Clinical trials · District of Columbia
HIV clinical trials in District of Columbia
We’re tracking 18 recruiting hiv studies with a site in District of Columbia — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in District of Columbia
- NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Washington D.C., District of ColumbiaAges 18–70 - NCT06501781Recruiting
PUSH: Helping People with HIV and Substance Use
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
Washington D.C., District of ColumbiaAges 18–88 - NCT07044297RecruitingPhase 3
A study of a new long-acting shot to prevent HIV
This study tests an investigational long-acting shot (MK-8527) to prevent HIV. It is for HIV-negative people who are at higher risk through anal sex without condoms, and who have not used other long-acting HIV prevention before.
Washington D.C., District of ColumbiaAges 16 years+ - NCT00001281Recruiting
Understanding how HIV affects blood cells and body fluids
This research study examines how HIV works in the blood and body fluids of people with and without HIV. By studying blood samples, researchers hope to better understand HIV infection and develop better treatments.
Washington D.C., District of ColumbiaAges 18–120 - NCT04949464Recruiting
Smoking quit coaching plus lung scans for people with HIV
This study tests a behavior-change program to help people with HIV quit smoking, along with routine low-dose lung CT scans to find warning signs early. It’s a feasibility study, meaning the main goal is to see if the approach is practical and acceptable, and if people can follow through.
Washington D.C., District of ColumbiaAges 45–80 - NCT07650916RecruitingPhase 3
A study of two ultra-long-acting HIV shots
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
Washington D.C., District of ColumbiaAges 12 years+ - NCT06691243RecruitingPhase 2
Testing semaglutide for cocaine use in adults
This study tests if the diabetes drug semaglutide (also used for weight loss) can help reduce cocaine use in adults, including those living with HIV. It's free and lasts about 8 weeks.
Washington D.C., District of ColumbiaAges 18–65 - NCT06056544Enrolling by invitation
HIV prevention support for Black men who have sex with men
This study tests a personalized care coordination program to help Black men who have sex with men stay on HIV prevention. It focuses on men who are new to or have stopped PrEP and want to reduce their HIV risk.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06872307Recruiting
Helping Black men stay on PrEP
This study tests a new way to help Black men who have sex with men stay on PrEP (HIV prevention pills) over time. If you are at risk for HIV and have stopped taking PrEP for at least a month, you may be able to join and get support to keep taking it.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06624839RecruitingPhase 2
HPV vaccine study for people with and without HIV
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Washington D.C., District of ColumbiaAges 18–70 - NCT04855773Recruiting
Mobile text-message support to help people stay on PrEP
This trial tests whether phone-based (iPhone/Android) text-message support can improve how consistently people use PrEP, an HIV prevention medicine. It may help you stay on track with refills and clinic visits, especially if you’re at higher risk of stopping PrEP.
Washington D.C., District of ColumbiaAges 15 years+ - NCT07266831RecruitingPhase 2/Phase 3
Study of islatravir and ulonivirine for new HIV patients
This trial tests two new HIV medications, islatravir and ulonivirine, in people who have never taken HIV treatment before. It aims to see if this combination can safely control the virus.
Washington D.C., District of ColumbiaAges 18 years+ - NCT01206920Recruiting
DC study following HIV prevention and care experiences over time
This study follows people who receive HIV care in Washington, DC and people using HIV prevention medicines (like PrEP) to understand health needs and outcomes over time. It may help improve how HIV care and prevention are delivered in local clinics.
Washington D.C., District of ColumbiaAges Any age - NCT05529342Enrolling by invitation
Long-term follow-up for a prior gene-cell treatment
This study follows people long-term after receiving a specific gene-cell treatment called AGT103-T. It helps researchers check long-term safety and outcomes, which can guide future care for others.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06046079Recruiting
HIV Prevention Service Use Study in Washington DC
This study looks at how people in the Washington, DC area use HIV prevention services. It focuses on those who are HIV-negative and either new to PrEP, taking daily PrEP pills, or getting long-acting injectable PrEP.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04499053RecruitingPhase 2
Durvalumab and tremelimumab with chemotherapy for advanced lung cancer in HIV
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05663502Recruiting
Donate blood and tissue samples for HIV-related cancer research
This study collects blood and tissue samples to help researchers learn more about cancers related to HIV/AIDS. You may be able to join if you’re 18+ and have HIV and a cancer diagnosis, or (if HIV-negative) a certain cancer that is closely linked to AIDS-related cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Washington D.C., District of ColumbiaAges 6–12
HIV trials by city in District of Columbia
Where these studies are running in District of Columbia
Institutions with a site for the recruiting hiv studies listed above.
- Whitman-Walker Health · 6 studies
- George Washington University Hospital · 3 studies
- Georgetown University Medical Center · 3 studies
- MedStar Washington Hospital Center · 3 studies
- Us Helping Us, People Into Living Inc. · 3 studies
- GSK Investigational Site · 2 studies
- HIPS · 2 studies
- Washington Health Institute · 2 studies
What taking part in a hiv study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
HIV trials in other states
Common questions
- Are there hiv clinical trials in District of Columbia?
- Yes. We're currently tracking 18 recruiting hiv studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hiv study in District of Columbia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in District of Columbia to take part?
- Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hiv studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.